cbdMD (YCBD) Amortization of Deferred Charges (2016 - 2025)
cbdMD (YCBD) posted Amortization of Deferred Charges of $171188.0 for Q4 2025, little changed sequentially from $170472.0 in Q3 2025, and up 316.2% YoY from $41131.0 in Q4 2024.
cbdMD (YCBD) Amortization of Deferred Charges (2016 - 2025) Analysis & Trends
cbdMD has reported Amortization of Deferred Charges for 7 years, with the latest figure at $171188.0 in Q4 2025.
- Quarterly Amortization of Deferred Charges rose 316.2% year-over-year to $171188.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $799838.0 (up 89.85% YoY) and the FY2025 annual result came in at $669781.0, changed 0.13% from the prior year.
- Amortization of Deferred Charges held at $171188.0 in Q4 2025 per YCBD's latest filing, from $170472.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $318017.0 in Q4 2021 and troughed at -$211778.0 in Q3 2024.
- A 5-year average of $222099.1 and a median of $276636.0 in 2022 frame the typical range for Amortization of Deferred Charges.
- The sharpest annual moves came in 2024 and 2025: Amortization of Deferred Charges plunged 173.82% in 2024, then jumped 316.2% in 2025.
- Over 5 years, Amortization of Deferred Charges stood at $318017.0 in 2021, then slipped by 13.01% to $276636.0 in 2022, then climbed by 5.0% to $290459.0 in 2023, then sank by 85.84% to $41131.0 in 2024, then surged by 316.2% to $171188.0 in 2025.
- According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $171188.0, $170472.0, and $168340.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | cbdMD | 5.41 Mn | 3.29 Mn | 3.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 171,188.00 |
| Dec 31, 2025 | 171,188.00 |
| Sep 30, 2025 | 170,472.00 |
| Sep 30, 2025 | 170,472.00 |
| Jun 30, 2025 | 168,340.00 |
| Jun 30, 2025 | 168,340.00 |
| Mar 31, 2025 | 289,838.00 |
| Mar 31, 2025 | 289,838.00 |
| Dec 31, 2024 | 41,131.00 |
| Dec 31, 2024 | 41,131.00 |
| Sep 30, 2024 | -211,778.00 |
| Sep 30, 2024 | -211,778.00 |
| Jun 30, 2024 | 297,825.00 |
| Jun 30, 2024 | 297,825.00 |
| Mar 31, 2024 | 294,115.00 |
| Mar 31, 2024 | 294,115.00 |
| Dec 31, 2023 | 290,459.00 |
| Dec 31, 2023 | 290,459.00 |
| Sep 30, 2023 | 286,897.00 |
| Sep 30, 2023 | 286,897.00 |